Fund profile / United Kingdom

Epidarex Capital Fund IV

Geography: United Kingdom
Stage: Seed
Fund size: €122M
Focus: Biotech and MedTech
Signals: Published

N°01 / About

About Epidarex Capital Fund IV

Transatlantic life-science fund secured $145M first close for Fund IV to fuel early-stage drug discovery and healthtech startups in the UK and US.

N°02 / Thesis

Investment Focus

Location / RegionUnited Kingdom

Funding StageSeed

Industry Focus

Biotech

MedTech

Investor Signals Profile

active

Sweet Spot

Rare disease biotech founders with clinical validation

immunology

rare disease

nephrology

biopharma

complement biology

oncolytic immunotherapy

oncology

cardiometabolic

inflammation

peripheral artery disease

Bullish Signals

Portfolio co Apellis acquired by Biogenexternal

Biogen-Apellis deal boosts nephrology thesiswebsite

Exit validates immunology/rare disease focuswebsite

Theolytics Phase 1 trial first patient dosedwebsite

Ovarian cancer trial recruitment on trackwebsite

THEO-260 IP dosing in platinum-resistant ovarian cancerwebsite

NodThera cardiometabolic data published JACCexternal

Ruvonoflast inflammation-at-source mechanism validated clinicallyexternal

NodThera JACC publication demonstrates cardiometabolic risk reductionexternal

Fund IV launch signals continued deployment capacityexternal

Rezera ruvonoflast met primary RESOLVE-1 endpointexternal

Favorable safety profile inflammation Phase 2external

Phase 3 PAD trial regulatory alignment achievedexternal

Rezera Phase 3 initiation imminent PAD indicationexternal

Contrarian Signals

No contrarian signals recorded.

Founder Do's

Target rare/serious diseases with unmet need

Pursue peer-reviewed clinical validation early

Build IP moats in immunology pathways

Publish cardiometabolic/inflammation data in top journals

Achieve regulatory alignment pre-Phase 3

Founder Don'ts

Avoid crowded oncology indications without differentiation

Skip robust clinical data before scale

22 signals on Epidarex Capital Fund IV

14 bullish · 5 pitch do's · 2 don'ts · 1 GP profile, each with its source. From €9/month, cancel anytime.

See a signal free View Plans Browse all Signal Profiles →

Facts

Fund Overview

Fund Size€122M

Saves0

Website

People

Key People

Sinclair Dunlop

UnknownPartner

N°04 / See also

Related Funds

Lightrock Accelerate7

Fund size$500M

Location: United Kingdom
Stage: Growth
Focus: Energy Tech, Climate Sustainability, Mobility Transport, Evs Charging
Manager: Lightrock (LGT Group)

Growth

Energy Tech

Climate Sustainability

Mobility Transport

Evs Charging

Brighteye Ventures Fund III

Fund size$72

Location: United Kingdom
Stage: Pre Seed
Focus

Pre Seed

Angular Ventures (III)

Fund size$125M

Location: United Kingdom
Stage: Pre Seed
Focus: Ai Ml, Climate Sustainability
Manager: Gil Dibner

Pre Seed

Ai Ml

Climate Sustainability